38154-40-4

Usage

Uses

Used in Pharmaceutical Synthesis:
4-Chloro-2-ethylquinazoline is used as a building block for the synthesis of pharmaceuticals, leveraging its quinazoline-based structure to contribute to the development of new drugs with potential therapeutic benefits.
Used in Agrochemical Synthesis:
4-Chloro-2-ethylquinazoline is also utilized as a building block in the synthesis of agrochemicals, where its chemical properties can be harnessed to create effective products for agricultural applications.
Used in Medicinal Chemistry Research:
4-Chloro-2-ethylquinazoline is used as a research compound in medicinal chemistry, where its biological activities are explored for potential applications in drug discovery and development. Its quinazoline structure may offer insights into novel mechanisms of action or therapeutic targets.

InChI:InChI=1/C10H9ClN2/c1-2-9-12-8-6-4-3-5-7(8)10(11)13-9/h3-6H,2H2,1H3

Upstream product

• 3137-64-2 2-Ethyl-quinazolin-4-ol 
• 19165-26-5 2-(propionylamino)benzoic acid 
• 118-92-3 anthranilic acid 
• 21411-14-3 propionamidobenzamide 
• 3137-64-2 2-ethyl-3H-quinazolin-4-one 

Relevant academic research and scientific papers

Discovery of N-(4-methoxyphenyl)-N,2-dimethylquinazolin-4-amine, a potent apoptosis inducer and efficacious anticancer agent with high blood brain barrier penetration

As a continuation of our structure-activity relationship (SAR) studies on 4-anilinoquinazolines as potent apoptosis inducers and to identify anticancer development candidates, we explored the replacement of the 2-Cl group in our lead compound 2-chloro-N-(4-methoxyphenyl)-N-methylquinazolin-4-amine (6b, EP128265, MPI-0441138) by other functional groups. This SAR study and lead optimization resulted in the identification of N-(4-methoxyphenyl)-N,2- dimethylquinazolin-4-amine (6h, EP128495, MPC-6827) as an anticancer clinical candidate. Compound 6h was found to be a potent apoptosis inducer with EC 50 of 2 nM in our cell-based apoptosis induction assay. It also has excellent blood brain barrier penetration, and is highly efficacious in human MX-1 breast and other mouse xenograft cancer models.

Phosphodiesterase inhibitory properties of losartan. Design and synthesis of new lead compounds

A 4-centre PDE 4 pharmacophore search has been carried out in several 3D-databases containing compounds belonging to different therapeutic areas. Losartan, an angiotensin-II antagonist, has been identified as a new lead compound for developing PDE 4 inhibitors. New families of compounds derived from losartan has been synthesized and their PDE inhibition has been measured.